166 related articles for article (PubMed ID: 15939344)
1. Platelet-derived growth factor receptor (PDGFR): a target for anticancer therapeutics.
Board R; Jayson GC
Drug Resist Updat; 2005; 8(1-2):75-83. PubMed ID: 15939344
[TBL] [Abstract][Full Text] [Related]
2. PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma.
Ostman A
Cytokine Growth Factor Rev; 2004 Aug; 15(4):275-86. PubMed ID: 15207817
[TBL] [Abstract][Full Text] [Related]
3. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic derivatives of platelet-derived growth factor receptors.
Jones AV; Cross NC
Cell Mol Life Sci; 2004 Dec; 61(23):2912-23. PubMed ID: 15583853
[TBL] [Abstract][Full Text] [Related]
5. Delphinidin, a dietary anthocyanidin, inhibits platelet-derived growth factor ligand/receptor (PDGF/PDGFR) signaling.
Lamy S; Beaulieu E; Labbé D; Bédard V; Moghrabi A; Barrette S; Gingras D; Béliveau R
Carcinogenesis; 2008 May; 29(5):1033-41. PubMed ID: 18339683
[TBL] [Abstract][Full Text] [Related]
6. Platelet-derived growth factor (PDGF) and glial tumorigenesis.
Shih AH; Holland EC
Cancer Lett; 2006 Feb; 232(2):139-47. PubMed ID: 16139423
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic targeting of platelet-derived growth factor receptors in solid tumors.
Ehnman M; Östman A
Expert Opin Investig Drugs; 2014 Feb; 23(2):211-26. PubMed ID: 24206431
[TBL] [Abstract][Full Text] [Related]
8. The platelet-derived growth factor receptor as a target for vascular endothelial growth factor-mediated anti-angiogenetic therapy in head and neck cancer.
Bran B; Bran G; Hörmann K; Riedel F
Int J Oncol; 2009 Jan; 34(1):255-61. PubMed ID: 19082496
[TBL] [Abstract][Full Text] [Related]
9. Receptor tyrosine kinase inhibitors as anti-angiogenic agents.
Kim DW; Lu B; Hallahan DE
Curr Opin Investig Drugs; 2004 Jun; 5(6):597-604. PubMed ID: 15242247
[TBL] [Abstract][Full Text] [Related]
10. Exploring multi-targeting strategies for the treatment of gliomas.
Omuro AM
Curr Opin Investig Drugs; 2008 Dec; 9(12):1287-95. PubMed ID: 19037835
[TBL] [Abstract][Full Text] [Related]
11. Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.
Dai Y
Expert Opin Ther Pat; 2010 Jul; 20(7):885-97. PubMed ID: 20509775
[TBL] [Abstract][Full Text] [Related]
12. Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors.
Fernando NT; Koch M; Rothrock C; Gollogly LK; D'Amore PA; Ryeom S; Yoon SS
Clin Cancer Res; 2008 Mar; 14(5):1529-39. PubMed ID: 18316578
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic application of noncytotoxic molecular targeted therapy in gliomas: growth factor receptors and angiogenesis inhibitors.
Idbaih A; Ducray F; Sierra Del Rio M; Hoang-Xuan K; Delattre JY
Oncologist; 2008 Sep; 13(9):978-92. PubMed ID: 18779539
[TBL] [Abstract][Full Text] [Related]
14. Anticancer therapeutics: "Addictive" targets, multi-targeted drugs, new drug combinations.
Broxterman HJ; Georgopapadakou NH
Drug Resist Updat; 2005 Aug; 8(4):183-97. PubMed ID: 16154800
[TBL] [Abstract][Full Text] [Related]
15. Upregulated expression of PDGF receptor beta in endocrine pancreatic tumors and metastases compared to normal endocrine pancreas.
Fjällskog ML; Hessman O; Eriksson B; Janson ET
Acta Oncol; 2007; 46(6):741-6. PubMed ID: 17653895
[TBL] [Abstract][Full Text] [Related]
16. Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume.
Jayson GC; Parker GJ; Mullamitha S; Valle JW; Saunders M; Broughton L; Lawrance J; Carrington B; Roberts C; Issa B; Buckley DL; Cheung S; Davies K; Watson Y; Zinkewich-Péotti K; Rolfe L; Jackson A
J Clin Oncol; 2005 Feb; 23(5):973-81. PubMed ID: 15466784
[TBL] [Abstract][Full Text] [Related]
17. Targeted agents for the treatment of advanced renal cell carcinoma.
Stadler WM
Cancer; 2005 Dec; 104(11):2323-33. PubMed ID: 16240452
[TBL] [Abstract][Full Text] [Related]
18. Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis.
McDermott LA; Higgins B; Simcox M; Luk KC; Nevins T; Kolinsky K; Smith M; Yang H; Li JK; Chen Y; Ke J; Mallalieu N; Egan T; Kolis S; Railkar A; Gerber L; Liu JJ; Konzelmann F; Zhang Z; Flynn T; Morales O; Chen Y
Bioorg Med Chem Lett; 2006 Apr; 16(7):1950-3. PubMed ID: 16460940
[TBL] [Abstract][Full Text] [Related]
19. Tumoral angiogenesis: review of the literature.
Khosravi Shahi P; Fernández Pineda I
Cancer Invest; 2008 Feb; 26(1):104-8. PubMed ID: 18181052
[TBL] [Abstract][Full Text] [Related]
20. Developmental roles of platelet-derived growth factors.
Betsholtz C; Karlsson L; Lindahl P
Bioessays; 2001 Jun; 23(6):494-507. PubMed ID: 11385629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
